Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Over the past 10 years, targeting vascular endothelial growth factor A (VEGFA) has been widely pursued in the treatment of various cancers and ophthalmic diseases. Here, Ferrara and Adamis provide an overview of the discovery of VEGFA and the development of anti-VEGFA therapies, addressing key challenges and issues that remain in the application of these agents.